Page 5 - Genevant Sciences News Today

Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 -- Arbutus... | April 4, 2023

The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology but they did not "result in a settlement."

By Will Feuer Arbutus Biopharma Corp. and its licensee Genevant Sciences have filed a patent-infringement lawsuit against Pfizer Inc. and BioNTech SE related to the latters Covid-19 vaccine.... | April 4, 2023

Companies find new digs in a vibrant tech cluster close to hospitals and transit

By Will Feuer Arbutus Biopharma Corp. and its licensee Genevant Sciences have filed a patent-infringement lawsuit against Pfizer Inc. and BioNTech SE related to the latters Covid-19 vaccine.... | April 4, 2023

Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04,...

Arbutus Biopharma ABUS-Q on Tuesday sued U.S. drugmaker Pfizer Inc PFE-N and its German partner BioNTech SE BNTX-Q in a New Jersey district court, claiming…

Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.

Moderna will charge $130 for Covid vaccines, as though Americans haven’t paid enough already.

Added complexity, uncertain volume, and new responsibilities justify costs, chief executive says